SG11202105413QA - Methods for diagnosing and/or treating acute or chronic liver, kidney or lung disease - Google Patents

Methods for diagnosing and/or treating acute or chronic liver, kidney or lung disease

Info

Publication number
SG11202105413QA
SG11202105413QA SG11202105413QA SG11202105413QA SG11202105413QA SG 11202105413Q A SG11202105413Q A SG 11202105413QA SG 11202105413Q A SG11202105413Q A SG 11202105413QA SG 11202105413Q A SG11202105413Q A SG 11202105413QA SG 11202105413Q A SG11202105413Q A SG 11202105413QA
Authority
SG
Singapore
Prior art keywords
diagnosing
kidney
methods
lung disease
chronic liver
Prior art date
Application number
SG11202105413QA
Other languages
English (en)
Inventor
Jorge Simón
Chantar María Luz Martínez
De La Cruz Alfonso Martínez
Original Assignee
Asociacion Centro De Investig Cooperativa En Biociencias Cic Biogune
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asociacion Centro De Investig Cooperativa En Biociencias Cic Biogune filed Critical Asociacion Centro De Investig Cooperativa En Biociencias Cic Biogune
Publication of SG11202105413QA publication Critical patent/SG11202105413QA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
SG11202105413QA 2018-11-26 2019-11-26 Methods for diagnosing and/or treating acute or chronic liver, kidney or lung disease SG11202105413QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382853 2018-11-26
PCT/EP2019/082606 WO2020109316A1 (en) 2018-11-26 2019-11-26 Methods for diagnosing and/or treating acute or chronic liver, kidney or lung disease

Publications (1)

Publication Number Publication Date
SG11202105413QA true SG11202105413QA (en) 2021-06-29

Family

ID=64665077

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105413QA SG11202105413QA (en) 2018-11-26 2019-11-26 Methods for diagnosing and/or treating acute or chronic liver, kidney or lung disease

Country Status (12)

Country Link
US (1) US20220026444A1 (ja)
EP (1) EP3886851A1 (ja)
JP (1) JP2022515976A (ja)
KR (1) KR20210096143A (ja)
CN (1) CN113271943A (ja)
AU (1) AU2019390667A1 (ja)
BR (1) BR112021010174A2 (ja)
CA (1) CA3120842A1 (ja)
IL (1) IL283472A (ja)
MX (1) MX2021006210A (ja)
SG (1) SG11202105413QA (ja)
WO (1) WO2020109316A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021281511A1 (en) * 2020-05-27 2023-01-05 Asociación Centro de Investigación Cooperativa en Biociencias- CIC bioGUNE Nucleic acids for inhibiting expression of CNNM4 in a cell
KR102629955B1 (ko) * 2021-02-19 2024-01-25 가톨릭대학교 산학협력단 Ewsr1의 발현 또는 활성 촉진제를 포함하는 비알콜성 지방간염 예방 또는 치료용 약학적 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE340870T1 (de) 1998-04-03 2006-10-15 Compound Therapeutics Inc Adressierbare protein arrays
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP3310355B1 (en) * 2015-06-16 2020-11-11 University of Virginia Patent Foundation Ptp4a3 inhibitor for the treatment of cancer
CN108136005A (zh) * 2015-07-10 2018-06-08 佛蒙特大学及州农业学院 用于治疗药物诱导的疾病和病症的mcj抑制剂

Also Published As

Publication number Publication date
EP3886851A1 (en) 2021-10-06
AU2019390667A1 (en) 2021-07-22
US20220026444A1 (en) 2022-01-27
MX2021006210A (es) 2021-08-19
BR112021010174A2 (pt) 2021-11-03
JP2022515976A (ja) 2022-02-24
KR20210096143A (ko) 2021-08-04
IL283472A (en) 2021-07-29
CA3120842A1 (en) 2020-06-04
CN113271943A (zh) 2021-08-17
WO2020109316A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
EP3438282A4 (en) METHOD FOR SCREENING CANDIDATE SUBSTANCES FOR AN ACTIVE COMPONENT TO PREVENT OR TREAT AT LEAST ONE SELECTED DISEASE IN THE KIDNEY HYPOFUNCTION GROUP, CHRONIC KIDNEY DISEASE AND KIDNEY DEFICIENCY
SG11202103877SA (en) Privacy preserving validation and commit architecture
EP3647422A4 (en) KIT, DEVICE AND METHOD FOR DETECTING LUNG CANCER
IL263025A (en) A method and system for predicting the prognosis for kidney disease
IL286603A (en) Treatment employing anti-il-13r antibody or binding fragment thereof
IL283472A (en) Methods for diagnosing and/or treating acute or chronic liver, kidney or lung disease
EP3792363A4 (en) METHOD AND KIT FOR IDENTIFYING THE STATE OF LUNG CANCER
EP3801069A4 (en) MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
IL276009A (en) Kits and methods for diagnosing lung cancer
IL276097A (en) Methods for treating diabetes, jaundice, and inflammatory liver disease
SG11202011969WA (en) Methods for characterizing protein complexes
IL279174A (en) Methods for treating diabetic patients with chronic kidney disease
EP3877949A4 (en) SYSTEMS AND METHODS FOR SEMI-AUTOMATIC TUMOR SEGMENTATION
EP3674710C0 (en) LIVER DISEASE PREDICTION OR DIAGNOSTIC METHODS FOR PATIENTS WITH NAFLD
EP3775164A4 (en) LUNG CANCER DETERMINATION SYSTEM AND METHOD
EP3342864A4 (en) DIAGNOSTIC PROCEDURE FOR AUTOIMMUNE DISEASES, BIOMARKERS FOR THE DIAGNOSIS OF AUTOIMMUNE DISEASES AND ACTIVE AGGREGATE FOR THE PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASES
SG11202002088TA (en) Methods and compositions for treating chronic lung diseases
RS64666B1 (sr) Dulaglutid za tretman hronične bolesti bubrega
ZA201906997B (en) Methods of diagnosing and treating chronic kidney disease
EP3468564A4 (en) METHOD FOR DIAGNOSTICING AND TREATING METASTASIVE CANCER
EP3307781B8 (en) Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia
EP3352859A4 (en) QUANTIFICATION OF PROTEIN MET FOR THE TREATMENT OF CANCER
EP3217987A4 (en) Sglt-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease
EP3695224A4 (en) Prognosis and progression biomarkers for chronic kidney disease
PL3543702T3 (pl) Sposoby badania przesiewowego osobnika pod kątem ryzyka przewlekłej choroby nerek i sposób realizowany komputerowo